A detailed history of Exodus Point Capital Management, LP transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 53,500 shares of AUPH stock, worth $426,395. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,500
Holding current value
$426,395
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$6.75 - $10.44 $361,125 - $558,540
53,500 New
53,500 $480,000
Q3 2023

Nov 09, 2023

BUY
$7.77 - $12.27 $2.31 Million - $3.65 Million
297,782 Added 619.97%
345,814 $2.69 Million
Q2 2023

Aug 10, 2023

BUY
$8.96 - $11.69 $74,851 - $97,658
8,354 Added 21.05%
48,032 $465,000
Q1 2023

May 11, 2023

BUY
$5.94 - $11.27 $18,746 - $35,568
3,156 Added 8.64%
39,678 $435,000
Q4 2022

Feb 13, 2023

BUY
$4.11 - $8.14 $150,105 - $297,289
36,522 New
36,522 $158,000
Q3 2022

Nov 10, 2022

SELL
$6.66 - $12.39 $1.2 Million - $2.24 Million
-180,472 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$8.95 - $12.8 $234,024 - $334,694
26,148 Added 16.94%
180,472 $1.81 Million
Q1 2022

May 13, 2022

BUY
$10.05 - $22.48 $65,576 - $146,682
6,525 Added 4.41%
154,324 $1.91 Million
Q4 2021

Feb 11, 2022

BUY
$17.78 - $33.08 $2.63 Million - $4.89 Million
147,799 New
147,799 $3.38 Million
Q2 2021

Aug 16, 2021

SELL
$10.0 - $14.52 $113,360 - $164,598
-11,336 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$12.3 - $18.73 $139,432 - $212,323
11,336 New
11,336 $147,000
Q4 2020

Feb 16, 2021

SELL
$12.94 - $16.05 $284,524 - $352,907
-21,988 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$13.19 - $16.66 $290,021 - $366,320
21,988 New
21,988 $324,000
Q4 2019

Feb 14, 2020

SELL
$3.88 - $21.42 $110,192 - $608,328
-28,400 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$5.34 - $6.59 $151,656 - $187,156
28,400 New
28,400 $152,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.13B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.